PARVOLEX 200 MG
ACETYLCYSTEINE : 200 MG · DIN 02181460 · MYLAN PHARMACEUTICALS ULC
Health Canada status: CANCELLED POST MARKET
What is PARVOLEX?
PARVOLEX 200 MG contains ACETYLCYSTEINE : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02181460, held by MYLAN PHARMACEUTICALS ULC, supplied as LIQUID for ORAL ; INHALATION ; INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 09-May-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PARVOLEX used for?
As a mucolytic agent: Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid or inspissated mucous secretions in such conditions as; chronic bronchopulmonary disease such as emphysema, chronic bronchitis, lung abscess, tuberculosis, bronchiectasis, and primary amyioidosis of the lung; acute bronchopulmonary disease such as pneumonia, bronchitis and tracheobronchitis; pulmonary complications of cystic fibrosis; tracheostomy care, pulmonary complications associated with surgery; use during anesthesia; post-traumatic chest conditions and pulmonary collapse; diagnostic bronchial studies such as bronchograms, bronchospirometry and bronchial wedge catheterization. As an antidote for acetaminophen poisoning: Acetylcysteine is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02181460 |
|---|---|
| Brand name | PARVOLEX |
| Generic / active ingredient | ACETYLCYSTEINE : 200 MG |
| Manufacturer | MYLAN PHARMACEUTICALS ULC |
| Strength | 200 MG |
| Dosage form | LIQUID |
| Route of administration | ORAL ; INHALATION ; INTRAVENOUS |
| Schedule | Ethical |
| ATC code | R05CB01 ACETYLCYSTEINE |
| AHFS class | 24:32.04 ; 40:28.20 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 09-May-2022 |
| Original market date | 1999-04-01 00:00:00 |
How is it stored and handled?
Store at room temperature (15 – 30°C) if unopened. If previously opened, when used for inhalation or oral administration, unused portions should be stored in a refrigerator and used within 96 hours.
How is it supplied?
Lacquered rubber sloppered glass vials of 10 mL and 30 mL, in trays of 10.
Is ACETYLCYSTEINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code R05CB01 ACETYLCYSTEINE. 3 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACETYLCYSTEINE SOLUTION | 200 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02243098 |
| ACETYLCYSTEINE SOLUTION USP | 200 MG | SOLUTION | STERIMAX INC | MARKETED | DIN 02538431 |
| ACETYLCYSTEINE SOLUTION USP | 200 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02459906 |
| ACETYLCYSTEINE INJECTION | 200 MG | SOLUTION | TELIGENT OU | CANCELLED POST MARKET | DIN 02300435 |
| ACETYLCYSTEINE INJECTION | 200 MG | SOLUTION | AURO PHARMA INC | APPROVED | DIN 02528274 |
| ACETYLCYSTEINE INJECTION | 200 MG | SOLUTION | EUGIA PHARMA INC. | APPROVED | DIN 02534908 |
| MUCOMYST | 200 MG | SOLUTION | WELLSPRING PHARMACEUTICAL CANADA CORP | CANCELLED POST MARKET | DIN 02091526 |
| MUCOMYST INJ 200MG/ML | 200 MG | LIQUID | BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB | CANCELLED POST MARKET | DIN 00606235 |
| PARVOLEX LIQ IV 200MG/ML | 200 MG | LIQUID | BIONICHE PHARMA (CANADA) LTD | CANCELLED POST MARKET | DIN 02094738 |
Who else supplies ACETYLCYSTEINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ACETYLCYSTEINE appears in 117 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.